Goldman Sachs reiterates CKD at Buy, raises target price to ¥10,000

Overview

This report is Goldman Sachs' company research and rating update on CKD (6407.T). It notes that CKD's FY3/26 results were clearly above expectations, and the core components business accelerated as semiconductor conditions improved, with strong 4Q margin performance. Goldman Sachs believes the company's FY3/27 guidance is broadly in line with market expectations, but given CKD's historically conservative initial guidance and the strong momentum in 4Q orders and profits, actual earnings could still significantly exceed guidance.

Core views

Goldman Sachs' core view is that CKD is one of the Japanese machinery names with the highest semiconductor exposure and one of the FA stocks best positioned to benefit from the structural upcycle in AI and semiconductors. The company's components business utilization, overseas capacity expansion, margin control, and capital management all support further earnings upside; meanwhile, its valuation is still considered inexpensive relative to other FA stocks. Based on higher earnings forecasts, roll-forward of the valuation base, and an increase in the sector relative premium from 0% to +30%, Goldman Sachs reiterates Buy and sharply raises its target price.

Analysis framework

The report mainly uses earnings comparisons, assessment of company guidance, segment margin analysis, capacity and order trend judgment, interpretation of management's medium-term plan, and an EV/EBITDA relative valuation framework. Goldman Sachs compares CKD's FY3/26 actual operating profit, FY3/27 guidance, and FY3/28 earnings forecast with its own estimates and the I/B/E/S consensus, and adjusts the target price based on the semiconductor cycle, FA peer valuations, and the company's capital allocation policy.

Methodology notes

• Valuation methodsEV/EBITDA relative valuation

  The 12-month target price is based on the FY3/28E EV/EBITDA average, using a 10x industry average multiple plus a 30% relative premium.

  Goldman Sachs rolled the target price calculation base forward from the FY3/27-28 average to FY3/28, and, due to recent valuation expansion, raised CKD's sector relative premium from 0% to +30%, driving the target price higher to ¥10,000.

• factor_profileGS Factor Profile

  Goldman Sachs' factor profile compares growth, financial returns, valuation multiples, and overall score.

  This framework evaluates stock characteristics using standardized rankings across metrics such as sales growth, EBITDA growth, EPS growth, ROE, ROCE, CROCI, P/E, P/B, and EV/EBITDA.

• corporate_activityM&A Rank

  Goldman Sachs uses a 1-to-3 score to assess the probability of a company becoming an M&A target.

  M&A Rank 1 indicates a relatively high probability of being acquired, 2 indicates a medium probability, and 3 indicates a low probability; if the score is 1 or 2, an M&A factor is usually incorporated into the target price.

• databaseQuantum

  Goldman Sachs Quantum is its proprietary financial database.

  The database is used to obtain historical financial statements, forecasts, and ratios, supporting both single-company deep dives and cross-industry comparisons.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• CKD (6407.T)

  Research coverage; Goldman Sachs reiterates Buy and raises the target price.

  Strengths

  High semiconductor exposure, record 4Q profit in the components business, OPM of 17.0%, additional upside in China and Malaysia capacity, and a medium-term plan emphasizing margins, ROE, and capital management.

  Weaknesses

  FY3/27 company guidance is below Goldman Sachs' prior more optimistic forecast; earnings remain exposed to silicon cycle volatility.

  Comparison

  Goldman Sachs views CKD as the FA stock with the highest semiconductor exposure in Japanese machinery coverage, and its valuation is still not expensive relative to other FA stocks.

  Risks

  Semiconductor demand weaker than expected, rising input costs, and fixed costs increasing faster than expected.

• Japan FA machinery stocks

  Comparable asset group and valuation reference.

  Strengths

  Benefit from the structural upcycle in AI and semiconductors.

  Weaknesses

  Valuation and earnings elasticity differ depending on each company's semiconductor exposure.

  Comparison

  CKD is viewed by Goldman Sachs as the FA stock with the clearest semiconductor exposure, and its mid/small-cap characteristics provide greater earnings leverage.

  Risks

  A pullback in sector valuations or a reversal in the semiconductor cycle would weigh on sector performance.

• Semiconductor cycle

  The key macro/industry driver for CKD's earnings and valuation re-rating.

  Strengths

  Conditions have improved significantly since late 2025, supporting stronger orders, sales, and components margins.

  Weaknesses

  The cycle is highly cyclical, and a slowdown in demand would affect earnings realization.

  Comparison

  CKD benefits more directly through its fluid control and components businesses.

  Risks

  Demand softening, supply chain disruptions, and a slowdown in customer capex.

Key data

• FY3/26 operating profit¥19.6bnAbove Goldman Sachs' estimate of ¥18.0bn and the I/B/E/S consensus of ¥17.7bn.
• FY3/27 operating profit guidance¥24.5bnClose to the I/B/E/S consensus of ¥24.3bn; Goldman Sachs views the guidance as conservative.
• 4Q operating profit in the components business¥6.8bnA quarterly record.
• 4Q OPM in the components business17.0%The second-highest level on record.
• Target price¥10,000Raised from the previous ¥6,800.
• Upside47.3%Corresponds to the report's 12-month target price.
• FY3/28E operating profit forecast¥37.0bnGoldman Sachs' forecast table shows the new forecast above the previous ¥33.5bn.
• FY3/28E EPS¥404.2From Goldman Sachs' forecast table.
• Medium-term plan targetsFY3/29 sales of more than ¥190bn, OPM above 13.7%, ROE above 10%Goldman Sachs views these targets as conservative, and management's wording emphasizes 'or above.'
• Shareholder returnMinimum dividend payout ratio of 40%One of the company's newly set shareholder return policies.

Impact & implications

If Goldman Sachs is correct, CKD will benefit simultaneously from a semiconductor demand recovery, an AI-related structural upcycle, release of components business capacity, margin improvement, and optimized capital management. Higher earnings forecasts and a better valuation premium together support the sharp target price increase; however, because the report also acknowledges that semiconductor demand, costs, and fixed expenses are the main downside risks, the investment conclusion is sensitive to the continuation of the semiconductor upcycle and the execution of capacity expansion.

Risks

• Semiconductor demand weaker than expected.
• A sharp increase in input costs.
• Fixed costs rising faster than expected.
• Semiconductor cycle volatility may lead to earnings volatility.
• If capacity expansion or overseas utilization improvement falls short of expectations, margin upside may be limited.

What to watch

• Whether FY3/27 actual operating profit significantly exceeds the company's ¥24.5bn guidance.
• Whether components business OPM can be maintained at or above the high level of 17.0%.
• Improvement in capacity utilization in China.
• The impact of the Hokuriku, Malaysia, and Northeast second factory projects on supply capacity and fixed costs.
• Whether the company can implement capital management measures such as ROE improvement, a 40% minimum dividend payout ratio, potential share buybacks, and leverage usage.
• Whether semiconductor orders and AI-related demand continue to trend upward.